Nogapendekin

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.

Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.

Journal: Journal of medical economics

Published: March 04, 2026

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.

Journal: Cancers

Published: December 31, 2025

Intravesical gemcitabine (Inlexzo) for bladder cancer.

Intravesical gemcitabine (Inlexzo) for bladder cancer.

Journal: The Medical letter on drugs and therapeutics

Published: October 21, 2025

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.

Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Published: October 20, 2025

Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.

Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.

Journal: World journal of urology

Published: October 08, 2025

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.

Journal: The Journal of urology

Published: September 16, 2025

The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

Journal: Cancer immunology, immunotherapy : CII

Published: August 26, 2025

Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.

Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.

Journal: Current opinion in urology

Published: July 14, 2025

Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.

Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.

Journal: Translational andrology and urology

Published: July 09, 2025

Advances in Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer.

Advances in Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer.

Journal: Critical reviews in oncology/hematology

Published: June 07, 2025

Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.

Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.

Journal: Cancer medicine

Published: June 06, 2025

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

Journal: European urology

Published: May 15, 2025

Showing 1-12 of 29

Last Updated: 04/28/2026